ATE320444T1 - Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren - Google Patents

Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren

Info

Publication number
ATE320444T1
ATE320444T1 AT92307785T AT92307785T ATE320444T1 AT E320444 T1 ATE320444 T1 AT E320444T1 AT 92307785 T AT92307785 T AT 92307785T AT 92307785 T AT92307785 T AT 92307785T AT E320444 T1 ATE320444 T1 AT E320444T1
Authority
AT
Austria
Prior art keywords
peptides
hbv
virus
cytotoxic
hepatitis
Prior art date
Application number
AT92307785T
Other languages
English (en)
Inventor
Francis V Chisari
Carlo Ferrari
Amalia Penna
Gabriele Missale
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE320444T1 publication Critical patent/ATE320444T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT92307785T 1991-08-26 1992-08-26 Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren ATE320444T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74954091A 1991-08-26 1991-08-26

Publications (1)

Publication Number Publication Date
ATE320444T1 true ATE320444T1 (de) 2006-04-15

Family

ID=25014174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92307785T ATE320444T1 (de) 1991-08-26 1992-08-26 Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren

Country Status (19)

Country Link
EP (1) EP0534618B1 (de)
JP (3) JP3566284B2 (de)
AT (1) ATE320444T1 (de)
AU (1) AU679901B2 (de)
BG (1) BG98522A (de)
CA (1) CA2115927C (de)
CZ (1) CZ42894A3 (de)
DE (1) DE69233607T2 (de)
DK (1) DK0534618T3 (de)
ES (1) ES2262132T3 (de)
FI (1) FI940919A (de)
HU (1) HUT67529A (de)
IL (1) IL102963A0 (de)
NO (1) NO940661L (de)
NZ (2) NZ244102A (de)
OA (1) OA09889A (de)
PT (1) PT534618E (de)
WO (1) WO1993003753A1 (de)
ZA (1) ZA926440B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
EP1704868A1 (de) * 1992-08-07 2006-09-27 Pharmexa Inc. HLA Bindepeptide und ihre Verwendungen
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
ATE227118T1 (de) * 1993-08-02 2002-11-15 Scripps Research Inst Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
EP1049711B1 (de) * 1998-01-19 2003-12-10 Mogam Biotechnology Research Institute Liposomen, enthaltend peptidantigene, welche vom x-protein aus hepatitis b virus abstammen
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
GB0328753D0 (en) * 2003-12-11 2004-01-14 Royal Veterinary College The Hepatitis B vaccines
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
GB201223386D0 (en) 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
JP2017525681A (ja) * 2014-07-22 2017-09-07 アリオス バイオファーマ インク. パラミクソウイルスの治療方法
KR20230030032A (ko) 2016-06-20 2023-03-03 아이에스에이 파마슈티컬즈 비.브이. 펩타이드 백신의 제형
US20230087348A1 (en) * 2019-01-11 2023-03-23 Agency For Science, Technology And Research Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939900A (de) * 1972-08-25 1974-04-13
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
GB9016727D0 (en) * 1990-07-31 1990-09-12 Clonit Spa Amino acid residue sequence of hepatitis b core antigen

Also Published As

Publication number Publication date
JP2003267997A (ja) 2003-09-25
IL102963A0 (en) 1993-01-31
EP0534618A3 (en) 1993-06-30
HUT67529A (en) 1995-04-28
EP0534618A2 (de) 1993-03-31
JP3694299B2 (ja) 2005-09-14
NO940661D0 (no) 1994-02-25
JP3694300B2 (ja) 2005-09-14
FI940919A0 (fi) 1994-02-25
FI940919A (fi) 1994-04-25
WO1993003753A1 (en) 1993-03-04
EP0534618B1 (de) 2006-03-15
AU679901B2 (en) 1997-07-17
CA2115927A1 (en) 1993-03-04
ZA926440B (en) 1993-06-07
AU2540892A (en) 1993-03-16
CZ42894A3 (en) 1995-02-15
JP2003300999A (ja) 2003-10-21
NO940661L (no) 1994-04-19
ES2262132T3 (es) 2006-11-16
PT534618E (pt) 2006-08-31
OA09889A (en) 1994-09-15
BG98522A (en) 1995-05-31
NZ244102A (en) 1996-12-20
HU9400582D0 (en) 1994-07-28
NZ270625A (en) 1996-12-20
DE69233607D1 (de) 2006-05-11
DK0534618T3 (da) 2006-07-24
JP3566284B2 (ja) 2004-09-15
DE69233607T2 (de) 2006-11-30
CA2115927C (en) 2009-04-21
JPH06510050A (ja) 1994-11-10

Similar Documents

Publication Publication Date Title
ATE320444T1 (de) Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
DE69431665D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
EP1018344A3 (de) HLA-reduzierte CTL-Epitope gegen Hepatite B-Virus
Mifune et al. Essential role of T cells in the postexposure prophylaxis of rabies in mice
DE68925660D1 (de) Peptidfragmente von HIV
ATE220332T1 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
DE69428112T2 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
RU94032103A (ru) Пептиды, фармацевтическая композиция, вакцина, конъюгат, способы лечения и идентификации
RU94038427A (ru) Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
DE69123252D1 (de) Kreuzreaktive immunisierung gegen influenza
Zourbas et al. Immunization of dental surgeons against hepatitis B virus infection.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0534618

Country of ref document: EP